Compare DHI & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | BDX |
|---|---|---|
| Founded | 1978 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8B | 43.0B |
| IPO Year | 1995 | 1998 |
| Metric | DHI | BDX |
|---|---|---|
| Price | $150.87 | $176.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $166.08 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | 1.19% | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.45 | 1.59 |
| Revenue | ★ $34,250,400,000.00 | $21,840,000,000.00 |
| Revenue This Year | $0.05 | N/A |
| Revenue Next Year | $5.85 | $3.02 |
| P/E Ratio | ★ $19.60 | $708.28 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $131.75 | $140.11 |
| 52 Week High | $183.62 | $213.08 |
| Indicator | DHI | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 72.56 |
| Support Level | $145.45 | $163.44 |
| Resistance Level | $150.95 | $196.05 |
| Average True Range (ATR) | 4.40 | 3.85 |
| MACD | 0.32 | 1.49 |
| Stochastic Oscillator | 51.62 | 91.51 |
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.